Structure-based design of anti-osteoporotic drug leads: an integrated approach (2009–2011)
Osteoporosis is a major health problem with a significant financial and social burden. Current treatments for this disease have undesirable side effects and necessitate a complicated dosage regime. A characteristic feature of osteoporosis is excessive bone resorption, which is mediated by a metalloenzyme. We will use sophisticated approaches including rational drug design, substrate/transition state analogue design and fragment-based screening to generate potent inhibitors of this enzyme as leads for the development of new drugs to treat osteoporosis. Ultimately, these new drugs will result in a lower burden on the healthcare system, and will lead to a significant improvement in the quality of life for Australia s aging population.